The Claim
In obese adults, a 5-week intervention with liraglutide at a dose of 3.0 mg leads to increased activation in the right orbitofrontal cortex in response to food cues, as observed in fMRI data when adjusted for concurrent weight or BMI changes, indicating a potential counter-regulatory neural adaptation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
When people with obesity take a weight-loss drug called liraglutide for 5 weeks, their brain's food-reward area becomes more active when they see food — even after accounting for weight loss, which might mean the brain is fighting back against losing weight.
See the scientific wording
In obese adults, 5 weeks of liraglutide 3.0 mg increases activation in the right orbitofrontal cortex (OFC) in response to food cues when fMRI data are adjusted for concurrent weight or BMI changes, suggesting a counter-regulatory neural adaptation.
What the research says
1 studyThe study found that after 5 weeks of liraglutide, the brain's reward area became more active in response to food when accounting for weight loss, which matches what the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.